List of Generics Companies with Phase 4 Active Clinical Trial - 21

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company based in Shijiazhuang, Hebei, China. The company focuses on the research, development, manufacture, and sale of a wide range of pharmaceutical products. With a strong emphasis on innovation, CSPC has a robust research and development team of over 2,000 members, including many with advanced degrees and international experience. Their R&D efforts span multiple locations, including Shijiazhuang, Shanghai, Beijing, and the United States. CSPC offers a diverse array of pharmaceutical products, including finished drugs like capsules, tablets, and injections, as well as bulk drugs such as active pharmaceutical ingredients. Their product range addresses various therapeutic areas, including oncology, cardiovascular health, respiratory conditions, anti-infectives, and diabetes management. The company also has an extensive pipeline of over 300 projects focused on innovative drug development, highlighting its commitment to advancing healthcare solutions. CSPC's products are available in multiple regions, including the Americas, Europe, and Asia, serving a broad customer base in the healthcare sector.

Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes FDA-approved branded prescription products. We are the largest publicly listed biopharmaceutical company founded and headquartered in Nashville, Tennessee. Nashville has become a leading center for health care in the United States, with over 300 companies headquartered here, and working in that industry. Cumberland is collaborating with Vanderbilt University and the Vanderbilt University Medical Center through a growing number of research and development programs. We are devoted to improving the quality of patient care and addressing poorly met medical needs. With a focus on underserved niche markets, we deliver products that serve patients in the U.S. market as well as internationally through select partnerships. Our commercial organization supports our branded products in the U.S., while our development team is working on new medicines for the future. Our primary focus is to improve patient care by providing differentiated products that offer clear advantages over other treatments. We also strive to deliver solutions that may help reduce costs for healthcare providers and, ultimately, patients.

At Endo, our far-reaching vision is simple: to help everyone we serve live their best life. As a specialty pharmaceutical company, we’re motivated by a strong sense of purpose to find better ways to meet unique medical needs. Our global team of passionate employees understands the importance of their work. We’re dedicated to supporting one another as we connect with communities and foster partnerships that elevate quality-of-life and bring the best treatments forward. Our uncompromising commitment results in the delivery of life-enhancing therapies. From intelligent product selection to commercialization, we strive to make a meaningful, tangible impact to help everyone live their best life. Endo has global headquarters in Malvern, Pennsylvania. Community Guidelines: 1. Be respectful. Everyone who visits our page should feel comfortable and respected. 2. If we see a comment that violates anything in the following list, it may be removed. • Comments that use profanity; personally attack or bully another individual; or are off-topic, misleading, factually inaccurate, political, spam, defamatory, discriminatory or promotional. • Comments that are excessively repetitive and/or disruptive to the community. • Comments that promote illegal activity, use copyrights or trademarks or are related to an ongoing legal matter. • Comments that appear to be medical advice. We reserve the right to remove a reply for any reason at any time. 3. Adverse Event Reporting: If we see a post about an adverse event, an Endo representative will need to contact you to find out more information to comply with regulatory guidelines. If you experience a side effect while using an Endo product, please consult your physician or pharmacist immediately. You may also report to the FDA at fda.gov/medwatch or 800-FDA-1088. Replies from other users do not necessarily reflect the views of Endo. We do not endorse content added by other users.

Eusol Biotech was founded in March 2005 in Taipei, Taiwan. The company is involved in the R&D and GMP process development of recombinant human acid fibroblast.

Biologics, Small Molecules

Jiangsu Hansoh Pharmaceutical Group Co., Ltd. was established in July, 1995. It has developed into a new pharmaceutical group featuring R&D, manufacture, sales and pharmaceutical investment of drugs. There are more than 40 products launched into the market which cover six therapeutic categories: oncology, antibiotics, psychotropic, antidiabetics, gastro-intestinal and cardiovascular area. Since its inception, Hansoh has evolved into a flagship enterprise for R&D and production in China, a Top 30 enterprise of China's Pharmaceutical Industry, and one of the most innovative pharmaceutical enterprises in China. Adhering to the concept of management innovation, technology innovation and product innovation, Hansoh will accelerate collection and fusion of development factors including top-level talents, innovative technology and lean manufacturing, along with peers in the international pharmaceutical field, hand in hand and shoulder by shoulder, to jointly endeavor bravely to contribute wisdom and strength to health of mankind.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mission: Managing Complexity. Improving Lives. Values: Quality, Integrity, Service Principal Executive Office: Mallinckrodt plc Damastown Industrial Estate Mulhuddart, Dublin 15 Ireland U.S. Headquarters: 675 McDonnell Blvd. St. Louis, MO 63042 USA Website: www.mallinckrodt.com Stock Ticker: MNK Corporate Blog: http://blog.mallinckrodt.com/ Careers Website: www.mallinckrodt.com/careers Investor Relations: http://www.mallinckrodt.com/investors

Qilu Pharmaceuticals is a leading Chinese pharmaceutical company founded in 1958, recognized as one of the top three players in China's pharmaceutical industry. The company operates as a vertically integrated enterprise, focusing on human medicines, veterinary medicines, and crop protection products. It has 12 subsidiaries and 11 manufacturing sites across China. Qilu's product portfolio includes over 300 finished dosage forms, making it a prominent manufacturer of injectables and solid-dose medications. The company also produces a wide range of active pharmaceutical ingredients (APIs) and has a robust pipeline with more than 200 generic drugs, 20–30 biosimilars, and 80–90 innovative drugs in development. With a global reach, Qilu exports products to over 100 countries and has established subsidiaries in the U.S., Europe, and Brazil. The company employs over 39,000 people worldwide, with a strong emphasis on affordable medicines and improving global health.

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

Was established in 1993 and is headquartered in the core area of ​​the Eastern Smart City of Guangzhou, covering an area of ​​50,000 square meters. It is the world's leading bioprotein biopharmaceutical company, focusing on the sales and development of biopharmaceuticals in the field of critical illness. and production. The company adheres to the core values ​​of "integrity, integrity; passion, perseverance; commitment, efficiency; care, participation; innovation, learning; cooperation, communication", and owns the national Class II new drug (domestic exclusive variety) Templuoan® (urinol for injection) The company has the exclusive distribution rights in mainland China for the world's first Class 1 new drug Kailikan® (Eurexalin for injection), and the first-line drug Bonroli (ibandronic acid injection) in the field of tumor bone metastasis treatment.

Tolmar is a Northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. Tolmar develops and manufactures both proprietary and generic pharmaceutical products with specific focus in dermatology, oncology, and specialty injectable therapeutic areas.

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients' needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris' passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris' NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company's success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways including through our Diversity & Inclusion Committee and our Women's Business Council to help to ensure every employee's voice is heard. After all, it is our daily interactions with one another that build and sustain our culture which fuels our growth.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.twitter.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.